Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
7.01 AUD
-1.54%
Market Closed
Updated:
May 10, 2024
Mayne Pharma Group Ltd
Operating Expenses
|
Mayne Pharma Group Ltd
Operating Expenses Peer Comparison
Comparables:
RCE
NEU
BOT
PBP
C
CU6
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Expenses
-AU$255.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Operating Expenses
-AU$17.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Expenses
-AU$32.7m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-11%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Expenses
-AU$18.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-29%
|
|
|
Probiotec Ltd
ASX:PBP
|
Operating Expenses
-AU$46.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-7%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Expenses
-AU$26.4m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Operating Expenses?
Operating Expenses
-255.9m
AUD
-255.9m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Operating Expenses amounts to -255.9m AUD.
What is Mayne Pharma Group Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-3%
-3%
Over the last year, the Operating Expenses growth was -95%. The average annual Operating Expenses growth rates for Mayne Pharma Group Ltd have been -7% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
